Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5258185 | 0.83 | DRD2 (0.51) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL3763682 | 0.81 | DRD2 (0.58) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL7471717 | 0.81 | NPC1 (0.46) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11348622 | 0.81 | MCL1 (0.59) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL17637581 | 0.79 | DRD2 (0.61) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL143430 | 0.79 | NQO1 (0.59) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL8778611 | 0.78 | DRD2 (0.51) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL14536644 | 0.77 | RAB9A (0.51) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL27762926 | 0.77 | ALDH1A1 (0.53) | DRD2DRD4DRD3RAB9ANPC1 | |
| SCHEMBL22322049 | 0.77 | ALDH1A1 (0.41) | DRD2DRD4DRD3RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671089-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2010-03-02 | — | — | US | claimed |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | XENOPORT, INC. (US) | 2010-01-07 | — | — | US | claimed |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-05-01 | — | — | US | claimed |
| US-7323585-B2 | Levodopa prodrugs, and compositions and uses thereof | XENOPORT, INC. (US) | 2008-01-29 | — | — | US | claimed |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2006-01-26 | — | — | US | claimed |
| WO-2005121070-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8598162-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-12-03 | — | — | US | disclosed |
| CN-102850336-A | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMA CO LTD | 2013-01-02 | — | — | CN | disclosed |
| EP-2287161-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| EP-2287162-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-05-09 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2284169-B1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMA CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | ARBOR PHARMACEUTICALS, LLC | 2006-01-26 | — | — | US | disclosed |
| WO-2005121070-A1 | LEVODOPA PRODRUGS, AND COMPOSITIONS AND USES THEREOF | XENOPORT, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-5090994-A | HETEROCYCLIC COMPOUNDS AND HERBICIDAL COMPOSITIONS CONTAINING THE COMPOUNDS AS EFFECTIVE COMPONENTS | AGRO-KANESHO CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
| EP-0384973-A2 | Heterocyclic compounds, method for preparing the same and herbicidal compositions containing the compounds as effective components | AGRO-KANESHO CO., LTD. (JP) | 1990-09-05 | — | — | EP | disclosed |
| EP-0078462-B1 | 1,2,4,6-THIATRIAZINE-1,1 DIOXIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTI-GROWTH AGENTS FOR UNWANTED PLANTS | BASF Aktiengesellschaft (DE) | 1986-01-15 | — | — | EP | disclosed |
| US-4472191-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1984-09-18 | — | — | US | disclosed |
| EP-0078462-A1 | 1,2,4,6-Thiatriazine-1,1 dioxides, process for their preparation and their use as anti-growth agents for unwanted plants | BASF Aktiengesellschaft (DE) | 1983-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020028-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | DRD2 70/4885DRD4 109/4885DRD3 144/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | DRD2 139/4885DRD4 181/4885DRD3 161/4885 |
| US-20080103200-A1 | Levodopa prodrugs, and compositions and uses thereof | COMT, DDT, DDC | DRD2 70/4885DRD4 109/4885DRD3 144/4885 |
| US-20100004332-A1 | Levodopa Prodrugs, and Compositions and Uses Thereof | COMT, DDT, DDC | DRD2 70/4885DRD4 109/4885DRD3 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.